JAK inhibitor: Introduction
Indian Journal of Dermatology, Venereology and Leprology · 10.07.2023 · 89 · 688-690
DOI: 10.25259/ijdvl_8_2023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, online erschienen am 10.07.2023. Verfasst von Siba P Raychaudhuri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and of Medicine/Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, UC Davis, CA, United States. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Skin Diseases, Autoimmune Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions factors. Several key cytokines use JAK-STAT signaling proteins to transduce intra-cellular signals which are involved in the pathogenesis of autoimmune and inflammatory diseases such as in psoriatic disease (psoriasis, psoriatic arthritis), atopic dermatitis, alopecia areata, vitiligo, rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, Sjogren’s syndrome, and other autoimmune diseases. In recent years, understandings of the molecular mechanisms of JAK-STAT pathway in the inflammatory proliferative cascades of autoimmune diseases has led to the development of JAK inhibitors and has opened a new dimension for the treatment of systemic and cutaneous inflammatory diseases. In this symposium we have provided a broad perspective on the use of Janus kinase inhibitors in cutaneous autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and of Medicine/Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, UC Davis, CA, United States.
- Department of Veterans Affairs, VA Sacramento Medical Center, Northern California Health Care, California, CA, United States.
Zitieren
APA
Raychaudhuri, S. P., & Raychaudhuri, S. K. (2023). JAK inhibitor: Introduction. Indian Journal of Dermatology, Venereology and Leprology, 89, 688-690. https://doi.org/10.25259/ijdvl_8_2023
Vancouver
Raychaudhuri SP, Raychaudhuri SK. JAK inhibitor: Introduction. Indian Journal of Dermatology, Venereology and Leprology. 2023;89:688-690. doi:10.25259/ijdvl_8_2023
BibTeX
@article{Raychaudhuri2023,
author = {Raychaudhuri, Siba P and Raychaudhuri, Smriti K},
title = {JAK inhibitor: Introduction},
journal = {Indian Journal of Dermatology, Venereology and Leprology},
year = {2023},
volume = {89},
pages = {688--690},
doi = {10.25259/ijdvl_8_2023}
}
EUVIMED